Assessing ABIVAX (ENXTPA:ABVX) After Its Huge Biotech Rally And Pipeline Headlines
- If you are wondering whether ABIVAX Société Anonyme is priced attractively after its huge run, or if the current share price already reflects the story, this article breaks down what the numbers say about value.
- The stock last closed at €109.40, with a 7 day return of 8.1%, a 30 day return showing a 0.9% decline, a year to date return showing a 4.9% decline, and a 1 year gain that is very large compared to where it started.
- Recent news coverage has focused on ABIVAX Société Anonyme as a high profile biotech name, with attention on its pipeline progress, financing activity, and position within the French pharmaceuticals and biotech space. These headlines help explain why sentiment around the stock has shifted so quickly. This makes a closer look at valuation especially useful.
- The company currently has a valuation score of 2 out of 6, so the rest of this article will compare what different valuation approaches say about the stock and then finish with a way to think about value that goes beyond any single model.
ABIVAX Société Anonyme scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: ABIVAX Société Anonyme Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return. The goal is to translate those future euros into a single estimated value per share right now.
For ABIVAX Société Anonyme, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of €171.7 million, so the starting point is firmly in negative territory. Analysts provide explicit cash flow estimates out to 2030, with free cash flow projected to reach €692 million in that year. Beyond that, Simply Wall St extrapolates further cash flows, rising into the billions of euros, using the growth pattern implied by the earlier years.
After discounting each of these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of €688.00 per share. Compared with the recent share price of €109.40, this implies the stock is 84.1% undervalued based on this set of assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests ABIVAX Société Anonyme is undervalued by 84.1%. Track this in your watchlist or portfolio, or discover 226 more high quality undervalued stocks.
Approach 2: ABIVAX Société Anonyme Price vs Book
For companies where current profits are not the key anchor, the price to book, or P/B, ratio is often more useful than earnings based measures, because it compares the share price with the accounting value of net assets on the balance sheet.
In general, higher growth potential and lower perceived risk can justify a higher “normal” P/B multiple, while slower expected growth or higher risk tend to point to a lower one. That is why simply looking at a single P/B number in isolation can be misleading.
ABIVAX Société Anonyme currently trades on a P/B of 16.65x, compared with the Biotechs industry average of 3.28x and a peer group average of 9.94x. Simply Wall St’s Fair Ratio is a proprietary estimate of what a reasonable P/B might be, given factors such as growth profile, industry, profit margins, market cap and company specific risks. This tends to be more tailored than a broad comparison with peers or the overall industry, because it adjusts for those company level characteristics rather than assuming one size fits all.
In this case, the Fair Ratio figure is not available, so it is not possible to reach a clear view on whether the current 16.65x P/B points to under, over, or roughly fair pricing.
Result: ABOUT RIGHT
P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 95 top founder-led companies.
Upgrade Your Decision Making: Choose your ABIVAX Société Anonyme Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a clear story that links your view of ABIVAX Société Anonyme’s pipeline, margins and revenue potential to a financial forecast, a fair value, and then a simple comparison with the current price that updates automatically as news or earnings arrive. On the Community page you might see one investor building a cautious Narrative that points to fair value of about €101.40, while another builds a more optimistic Narrative closer to €179.70. These different perspectives can help you decide what ABIVAX Société Anonyme story you agree with and how that lines up against today’s share price.
Do you think there's more to the story for ABIVAX Société Anonyme? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com